POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada

Abstract

The primary objective of this study was to evaluate the incremental cost-utility ratio (ICUR) for the adjuvant treatment of patients with resected EC/GEJC tumour in Canada. This analysis is based on outcomes of the phase 3 clinical trial, CheckMate 577, in which patients with resected EC/GEJC had statistically significant and clinically meaningful improvement in its primary endpoint, disease-free survival (DFS), versus placebo with an acceptable safety profile following neoadjuvant chemoradiotherapy.